ABINGDON HEALTH PLC

Regulatory Filings • Dec 18, 2025

National Storage Mechanism | Additional information

RNS Number : 0252M

Abingdon Health PLC

18 December 2025

Abingdon Health plc

("Abingdon Health" or "the Company")

European patent for AppDx® lateral flow smartphone reader

York, U.K. 18 December 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces the granting of an additional patent for its AppDx® lateral flow smartphone reader.

The new European patent "Assay Reading Method" with patent number EP4150565 has been granted and follows the recent granting of a similar patent in USA with patent number US 12,373,946 B2, with other patents already granted in UK.

AppDx® is a software development kit for reading colorimetric lateral-flow tests organized for Android™ and iOS® smartphone operating systems. AppDx® enables lateral-flow test readout from your pocket, enabled by a smartphone camera. It consists of a software application programming interface accessed as a library which contains algorithms for image processing and deep learning in order to read a lateral-flow test using a smartphone. The algorithms are customized and tuned for each test. The Abingdon Health AppDx® algorithm reads the lateral flow device qualitatively (e.g. positive/negative) and semi-quantitively (e.g. negative/high/medium/low).

Dr Chris Hand, Executive Chairman of Abingdon Health plc, commented:

"We are pleased to announce the granting of a further patent for our AppDx® lateral flow smartphone lateral flow reader. This is another tool available to our contract development and manufacturing customers and illustrates the continued innovation in the lateral flow market."

Enquiries:

Abingdon Health plc	www.abingdonhealth.com/investors/
Chris Hand, Executive Chairman		Via Walbrook PR
Tom Hayes, CFO
Walbrook PR (Media & Investor Relations)	Tel: +44 (0)20 7933 8780 or [email protected]
Paul McManus / Alice Woodings	Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

About Abingdon Health

Abingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base.   

The Group's CDMO (Contract Development and Manufacturing Organisation) expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format.  Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; from idea to commercial success. 

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK.  Its consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.   The Company's subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance evaluation to generate the required technical and data for regulatory approval for lateral flow and other in vitro diagnostic assays from its Doncaster, England facilities. 

Founded in 2008, Abingdon Health is headquartered in York, England with laboratories in Doncaster, England and laboratories and commercial offices in Madison, Wisconsin, USA.

Abingdon Health's brochure outlines the comprehensive support the Group can now provide to its international customers.  For more information visit: www.abingdonhealth.com.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFFSESWEISELE